Boresowicz Joanna, Kober Paulina, Rusetska Nataliia, Maksymowicz Maria, Goryca Krzysztof, Kunicki Jacek, Bonicki Wiesław, Bujko Mateusz
Department of Molecular and Translational Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland.
Neuro Endocrinol Lett. 2018 Mar;39(1):49-55.
Pituitary adenomas (PAs) are among the most frequent intracranial tumors in humans. Abnormal telomerase activity and telomere lengthening are features of tumor cells. They may result from mutations in TERT promoter region, gene amplification or aberrant DNA methylation pattern. Such changes were found in variety of tumors including those of brain. Aim of the study was to evaluate the incidence of TERT abnormalities and to assess their role in telomere lengthening in PAs.
Study involved 101 patients with PA including both nonfunctioning and functioning subtypes. Telomerase length as well as TERT mRNA level and gene amplification were estimated using quantitative PCR (qPCR). Promoter mutations were assessed using Sanger sequencing. The results from genome-wide DNA methylation profiling with HumanMethylation 450K (Illumina) were used for the analysis of TERT locus.
Variable telomere length was observed in patients, however no relationship with clinicopathological features was found. We observed a missense variant in TERT promoter in one patient only whereas increased TERT copy number were identified in 6 patients (5.6%). However no relationship between these results and telomere length or TERT expression was found. DNA methylation at TERT locus was not found to be changed when adenoma samples and normal tissue sections were compared.
The results indicate that telomerase abnormalities do not play a role in pathogenesis of pituitary tumors.
垂体腺瘤(PAs)是人类最常见的颅内肿瘤之一。端粒酶活性异常和端粒延长是肿瘤细胞的特征。它们可能源于TERT启动子区域的突变、基因扩增或异常的DNA甲基化模式。在包括脑肿瘤在内的多种肿瘤中都发现了此类变化。本研究的目的是评估TERT异常的发生率,并评估它们在垂体腺瘤端粒延长中的作用。
研究纳入了101例垂体腺瘤患者,包括无功能型和有功能型亚型。使用定量PCR(qPCR)估计端粒酶长度以及TERT mRNA水平和基因扩增情况。使用桑格测序法评估启动子突变。来自HumanMethylation 450K(Illumina)全基因组DNA甲基化谱分析的结果用于TERT基因座的分析。
在患者中观察到端粒长度存在差异,但未发现与临床病理特征有相关性。仅在1例患者中观察到TERT启动子的错义变异,而在6例患者(5.6%)中鉴定出TERT拷贝数增加。然而,未发现这些结果与端粒长度或TERT表达之间存在相关性。比较腺瘤样本和正常组织切片时,未发现TERT基因座的DNA甲基化发生变化。
结果表明端粒酶异常在垂体肿瘤发病机制中不起作用。